12 April 2018
Third World Network
New affordable hepatitis C combination treatment shows 97% cure rate
Results support a public health approach to hepatitis C
Drugs for Neglected Diseases initiative press release, 12 April 2018
PARIS, 12 April 2018 – An affordable hepatitis C combination treatment including the new drug candidate ravidasvir has been shown to be safe and effective, with extremely high cure rates for patients, including hard-to-treat cases, according to interim results from the Phase II/III STORM-C-1 trial presented by the non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) at the international Liver Conference in Paris.
“The results indicate that the sofosbuvir/ravidasvir combination is comparable to the very best hepatitis C therapies available today. It is priced affordably and could allow an alternative option in countries excluded from pharmaceutical company access programs,” said Bernard Pécoul Executive Director, DNDi.
The whole press release can be read here
The Malaysian ‘Government Use’ initiative to make treatment available in the public sector in Malaysia is reported in the HAIAP News April 2018.